Topical clindamycin preparations
AssigneeThe Upjohn Company
InventorsDonald E. Ayer, Carl A. Schlagel, Gordon L. Flynn
Life of this patent
Estimating the term…
Abstract
Disclosed is an anti-inflammatory compound, 6.alpha.,9.alpha.-di-fluoro-11.beta.,17.alpha.,21-trihydroxy-16.beta.-meth ylpregna-1,4-diene-3,20-dione 17,21-diacetate, and topical pharmaceutical formulations which include antimicrobial agents.
Claims10
A therapeutic composition for topical or local application for treatment of affected dermatosis comprising an anti-inflammatory therapeutic amount of 6.alpha.,9.alpha.-difluoro-11.beta., 17.alpha.,21-trihydroxy-16.beta.-methylpregna-1,4-diene-3,20-dione 17,21-diacetate, an antibacterial therapeutic amount of clindamycin or pharmaceutically acceptable salt or ester thereof and an antifungal therapeutic amount of chloroxine in association with a pharmaceutical carrier.
A therapeutic composition for topical or local application for treatment of infected dermatoses comprising an anti-inflammatory therapeutic amount of 6.alpha.,9.alpha.-difluoro-11.beta., 17.alpha.,21-trihydroxy-16.beta.-methylpregna-1,4-diene-3,20-dione 17,21-diacetate and an antibacterial therapeutic amount of clindamycin or a pharmaceutically acceptable salt or ester thereof in association with a pharmaceutical carrier.
Dependencies are inferred from the claim text.